Written in Blood |
|||||||
|
• 15.4 months in standard-risk disease ( 95 % CI 9.5-19.1 ; p = 0.5 for all comparisons )
“ The noteworthy difference in OS and PFS suggests that patients can easily be rescued with subsequent treatment regimens after progressing on PVD ,” the authors added .
The most common grade ≥3 hematologic AEs were neutropenia ( 70 %), leukopenia ( 36 %), and lymphopenia ( 20 %), and the
|
most common non-hematologic AE was fatigue ( 72 %).
Forty-two percent of patients required dose adjustments of pomalidomide ( n = 21 ) after a median of five cycles ( range = 2-32 cycles ), most of which were related to neutropenia . In addition , dose adjustments of bortezomib and dexamethasone were required in 16 percent and 28 percent of patients , respectively .
“ Even though the use of thromboprophylaxis
|
was mandatory in our study , the rate of venous thromboembolism events was higher than in previously reported clinical trials of pomalidomide and low-dose dexamethasone ( 10 % vs . 4 %),” the authors wrote .
The authors attributed the regimen ’ s tolerability to the once-weekly administration of bortezomib , which was associated with similar efficacy rates and lower incidence of grade ≥3 non-hematologic AEs compared with previous reports of twice-weekly dosing .
|
The study is limited by its small patient population , non-randomized design , and lack of a comparator arm .
Contributing authors report financial relationships with Celgene , Takeda Oncology , and Millennium Pharmaceuticals .
REFERENCE
Paludo J , Mikhael JR , LaPlant BR , et al . Pomalidomide , bortezomib and dexamethasone ( PVD ) for patients with relapsed , lenalidomide refractory multiple myeloma . Blood . 2017 July 6 . [ Epub ahead of print ]
|